$EGRX (Eagle Pharmaceuticals Inc.)

$EGRX {{ '2015-12-24T12:39:10+0000' | timeago}} • Announcement

Specialty pharmaceutical company $EGRX said the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. $EGRX will begin shipping Docetaxel Injection in Jan. 2016.

$AGN {{ '2017-09-25T15:26:35+0000' | timeago}} • Announcement

$AGN CFO Tessa Hilado has decided to retire from the company. Allergan has initiated a search to fill the position. Hilado, who joined the company in Dec 2014, will continue in her current role until a successor is named to ensure a smooth transition.

$AGN {{ '2017-09-25T12:23:08+0000' | timeago}} • Announcement

$AGN has authorized a new $2Bil share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually. The company also affirmed its 3Q17 revenue projection, which was issued on Aug 3, 2017.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$REGN {{ '2017-09-18T10:59:56+0000' | timeago}} • Announcement

Pharma company $REGN and healthcare firm $SNY said a study showed that Dupixent, which is indicated for the treatment of atopic dermatitis, significantly improved overall disease severity. It also met the primary end point - the proportion of patients that achieved a 75% or greater improvement at 16 weeks from baseline.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$REGN {{ '2017-09-11T11:11:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma. The investigational dupilumab lowered severe asthma attacks and improved lung function. The companies plan to submit a Supplemental Biologics License Application (sBLA) to the U.S. FDA by the end of this year.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$CELG {{ '2017-09-08T15:34:27+0000' | timeago}} • Announcement

$CELG to present data from multiple studies about the use of Abraxane to treat non-small lung cancer and pancreatic cancer. The data will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between Sept 8-12 in Madrid, Spain.

$INCY {{ '2017-09-08T12:59:10+0000' | timeago}} • Announcement

$INCY priced its underwritten public offering of 4.945MM shares of its common stock. The company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock. The offering is expected to close on Sept. 12, 2017.

$CELG {{ '2017-09-07T15:10:29+0000' | timeago}} • Announcement

$CELG gets a pause from FDA as it partially holds the drugmaker's five clinical trials and one clinical trial fully. All of these trials involve cancer drug Durvalumab. Celgene added that patients enrolled in the partial hold trials may remain on the treatment and those who are on full clinical hold trial will be discontinued from the treatment.

$AMGN {{ '2017-09-07T12:11:23+0000' | timeago}} • Announcement

$AMGN announced results from the PATHWAY Phase 2b trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a novel anti-thymic stromal lymphopoietin monoclonal antibody being developed by $AZN in collaboration with $AMGN.

$VRTX {{ '2017-09-06T14:56:39+0000' | timeago}} • Announcement

$VRTX has announced the appointment of Tom Graney as SVP and CFO with effect from Sept 13, 2017.  He will report to EVP and COO Ian Smith.  Graney will be responsible for the development and execution of the financial strategies and operations of Vertex's business plans. He was the CFO and SVP of Finance and Corporate Strategy at $IRWD.

$BAX {{ '2017-08-31T13:27:20+0000' | timeago}} • Announcement

$BAX and MATTER announced a new collaboration to drive forward innovation focused on improving the value and quality of healthcare. This new partnership builds on $BAX's recently announced research collaborations with Mayo Clinic, Tel Aviv University and Tel Aviv Sourasky Medical Center.

$INCY {{ '2017-08-31T12:36:56+0000' | timeago}} • Announcement

$INCY said a study conducted by the European Society for Medical Oncology revealed that epacadostat, the company’s selective IDO1 enzyme inhibitor, demonstrated strong and durable responses in patients with advanced melanoma, when administrated in combination with KEYTRUDA. The society is expected to release the detailed results next month.

$LLY {{ '2017-08-30T13:53:36+0000' | timeago}} • Announcement

$LLY to resubmit the New Drug Application for rheumatoid arthritis medication Baricitinib, to the U.S. FDA, before the end of January 2018. Last month, Lilly and its development and marketing partner $INCY announced that resubmission of Baricitinib will take at least 18 months.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

Recent Transcripts

EGRX (Eagle Pharmaceuticals Inc.)
Wednesday, August 9 2017 - 12:30pm
ZGNX (Zogenix, Inc.)
Tuesday, August 8 2017 - 8:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 12:30pm
XNCR (Xencor, Inc.)
Monday, August 7 2017 - 8:30pm
CORI (Corium International, Inc.)
Thursday, August 3 2017 - 9:00pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
INFI (Infinity Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
AET (Aetna Inc.)
Thursday, August 3 2017 - 12:30pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, August 3 2017 - 12:00pm
CNAT (Conatus Pharmaceuticals Inc.)
Wednesday, August 2 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, August 2 2017 - 12:00pm
CORT (Corcept Therapeutics Incorporated)
Tuesday, August 1 2017 - 9:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
AZN (AstraZeneca PLC)
Thursday, July 27 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm

AlphaGraphics you may like